Former CEO Peter Greenleaf was paid $5,858,590 in fiscal year 2025, ↓ down 8.7% from fiscal year 2024, the 42nd percentile of its disclosed peer group (SEC filing 0001600620-26-000039 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,858,590 ↓ Peter Greenleaf total, FY2025 | 42nd CEO pay percentile vs peers | 18:1 CEO-to-median pay ratio | 93.9% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AUPH's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Peter Greenleaf | $822,877 | $0 | $1,965,321 | $2,193,189 | $864,021 | $0 | $13,182 | $5,858,590 |
| Former Chief Executive Officer | ||||||||
| Matthew Donley | 567,636 | 0 | 559,600 | 624,484 | 425,727 | 0 | 59,641 | 2,237,088 |
| Former Chief Operating Officer | ||||||||
| Stephen Robertson | 481,900 | 0 | 568,557 | 634,473 | 361,425 | 0 | 80,155 | 2,126,510 |
| Chief Legal Officer, Corporate Secretary and Chief Compliance Officer | ||||||||
| Joseph Miller | 526,988 | 0 | 550,649 | 614,491 | 395,241 | 0 | 15,378 | 2,102,747 |
| Former Chief Financial Officer | ||||||||
| Gregory Keenan | 516,233 | 0 | 423,060 | 472,108 | 348,458 | 0 | 14,382 | 1,774,241 |
| Former Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Peter Greenleaf | $5,858,590 | $6,417,897 | $10,573,359 | ↓ −559,307 |
| Matthew Donley | 2,237,088 | 2,514,527 | 4,558,086 | ↓ −277,439 |
| Stephen Robertson | 2,126,510 | 2,216,429 | 3,598,254 | ↓ −89,919 |
| Joseph Miller | 2,102,747 | 2,297,805 | 3,976,937 | ↓ −195,058 |
| Gregory Keenan | 1,774,241 | 1,327,097 | 1,531,697 | ↑ +447,144 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Aurinia Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper AUPH reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses AUPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AUPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Peter Greenleaf | CEO | $5,858,590 |
| Joseph Miller | CFO | $2,102,747 |
| Matthew Donley | COO | $2,237,088 |
| Stephen Robertson | General Counsel | $2,126,510 |
| Gregory Keenan | Chief Medical Officer | $1,774,241 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Craig Johnson | Lead Independent Director | $276,686 |
| Dr. David R.W. Jayne | Former director (through FY2025) | $17,063 |
| Dr. Karen Smith | Former director (through FY2025) | $17,251 |
| Jeffrey Bailey | Independent Director | $274,873 |
| Jill Leversage | Former director (through FY2025) | $17,438 |
| Kathy Goetz | Independent Director | $372,694 |
| Kevin Tang | Chair of the Board | — |
| Tina S. Nova, Ph.D | Independent Director | $374,157 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joseph Miller | PSU | 2025-02-28 | 20,364 | 81,457 | — | 81,457 | $550,649 |
| Matthew Donley | PSU | 2025-02-28 | 20,695 | 82,781 | — | 82,781 | 559,600 |
| Peter Greenleaf | PSU | 2025-02-28 | 72,682 | 290,728 | — | 290,728 | 1,965,321 |
| Gregory Keenan | PSU | 2025-02-28 | 15,645 | 62,583 | — | 62,583 | 423,061 |
| Stephen Robertson | PSU | 2025-02-28 | 21,026 | 84,106 | — | 84,106 | 568,557 |
| Peter Greenleaf | OPTION | 2025-02-28 | — | — | 443,973 | — | 2,193,189 |
| Gregory Keenan | OPTION | 2025-02-28 | — | — | 95,570 | — | 472,108 |
| Matthew Donley | OPTION | 2025-02-28 | — | — | 126,416 | — | 624,484 |
| Joseph Miller | OPTION | 2025-02-28 | — | — | 124,393 | — | 614,491 |
| Stephen Robertson | OPTION | 2025-02-28 | — | — | 128,438 | — | 634,473 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Joseph Miller | $0 | $550,649 | $614,491 | 47.3% |
| Matthew Donley | 0 | 559,600 | 624,484 | 47.3% |
| Peter Greenleaf | 0 | 1,965,321 | 2,193,189 | 47.3% |
| Gregory Keenan | 0 | 423,061 | 472,108 | 47.3% |
| Stephen Robertson | 0 | 568,557 | 634,473 | 47.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Donley | Option | 126,416 | 7.55 | — |
| Peter Greenleaf | RSU | 441,026 | — | 7,034,365 |
| Peter Greenleaf | RSU | 290,728 | — | 4,637,112 |
| Peter Greenleaf | RSU | 222,469 | — | 3,548,381 |
| Matthew Donley | RSU | 144,444 | — | 2,303,882 |
| Joseph Miller | RSU | 130,769 | — | 2,085,766 |
| Stephen Robertson | RSU | 129,487 | — | 2,065,318 |
| Matthew Donley | RSU | 90,378 | — | 1,441,529 |
| Stephen Robertson | RSU | 84,106 | — | 1,341,491 |
| Matthew Donley | RSU | 82,781 | — | 1,320,357 |
| Peter Greenleaf | RSU | 82,692 | — | 1,318,937 |
| Joseph Miller | RSU | 81,457 | — | 1,299,239 |
| Joseph Miller | RSU | 76,474 | — | 1,219,760 |
| Stephen Robertson | RSU | 68,270 | — | 1,088,907 |
| Gregory Keenan | RSU | 62,583 | — | 998,199 |
| Gregory Keenan | RSU | 45,495 | — | 725,645 |
| Matthew Donley | RSU | 27,083 | — | 431,974 |
| Joseph Miller | RSU | 24,519 | — | 391,078 |
| Stephen Robertson | RSU | 24,279 | — | 387,250 |
| Gregory Keenan | RSU | 16,687 | — | 266,158 |
| Peter Greenleaf | Option | 443,973 | 7.55 | — |
| Joseph Miller | Option | 124,393 | 7.55 | — |
| Gregory Keenan | Option | 6,832 | 8.99 | — |
| Gregory Keenan | Option | 95,570 | 7.55 | — |
| Stephen Robertson | Option | 128,438 | 7.55 | — |
The Company's executive compensation program is designed to support the attraction, retention, and engagement of global talent while aligning pay with performance outcomes. It emphasizes a significant portion of variable, at-risk compensation tied to measurable corporate performance and long-term shareholder value, utilizing a mix of base salary, annual performance incentives, and long-term equity grants.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | WTW |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 66,398,971 | 4,315,143 | 609,384 | 93.9% | Passed |
| 2025 | 2025-05-15 | 58,851,313 | 17,180,345 | 889,047 | 77.4% | Passed |
| 2024 | 2024-06-14 | 30,780,033 | 45,321,684 | 522,314 | 40.45% | Failed |
| 2023 | 2023-05-17 | 26,853,822 | 42,750,367 | 686,879 | 38.58% | Failed |
| 2022 | 2022-05-17 | 33,050,501 | 10,490,227 | 610,231 | 75.91% | Passed |
| 2021 | 2021-06-07 | 30,963,547 | 29,072,414 | 813,763 | 51.58% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | 93.9%a |
| 2025 | 2025-05-15 | 77.4%b |
| 2024 | 2024-06-14 | 40.45%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 18 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $320,246 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tina S. Nova, Ph.DIndependent · Audit · Newly elected | $34,162 | $0 | $339,995 | — | — | $374,157 |
| Kathy GoetzIndependent · Compensation · Governance and Nomination · Newly elected | 32,699 | 0 | 339,995 | — | — | 372,694 |
| Craig JohnsonIndependent · Lead Independent Director · Audit (Chair) · Compensation (Chair) | 76,688 | 0 | 199,998 | — | — | 276,686 |
| Jeffrey BaileyIndependent · Audit · Compensation · Governance and Nomination (Chair) | 74,875 | 0 | 199,998 | — | — | 274,873 |
| Jill LeversageIndependent · Not standing for re-election · Departed during FY | 17,438 | 0 | 0 | — | — | 17,438 |
| Dr. Karen SmithIndependent · Not standing for re-election · Departed during FY | 17,251 | 0 | 0 | — | — | 17,251 |
| Dr. David R.W. JayneIndependent · Not standing for re-election · Departed during FY | 17,063 | 0 | 0 | — | — | 17,063 |
| Kevin TangEmployee director · Board Chair · Audit · Compensation · Governance & Nomination | 0 | — | 0 | — | — | 0 |
| Former DirectorsIndependent | — | — | — | — | — | — |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $270,176 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $270,176 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Aurinia Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Aurinia Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Pacira Biosciences Inc. | 2025 | Frank Lee | $935,308 | $9,215,500 | $0 | $738,810 | $11,636,917 |
| 2 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 3 | ARS Pharmaceuticals Inc. | 2025 | Richard Lowenthal | 700,000 | — | 6,176,110 | 315,000 | 9,656,400 |
| 4 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 5 | Arcutis Biotherapeutics Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 6 | MiMedx Group Inc. | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 7 | Sage Therapeutics Inc. | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 8 | Phathom Pharmaceuticals Inc. | 2025 | Steven Basta | 525,000 | 1,986,600 | 3,983,144 | 455,701 | 6,968,070 |
| 9 | Tarsus Pharmaceuticals Inc. | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 10 | Day One Biopharmaceuticals Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 11 | Evolus Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 12 | Aurinia Pharmaceuticals | 2025 | Peter Greenleaf | 822,877 | 1,965,321 | 2,193,189 | 864,021 | 5,858,590 |
| 13 | Innoviva Inc. | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 14 | Y-mAbs Therapeutics, Inc. | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 15 | Urogen Pharma Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 16 | Lexicon Pharmaceuticals Inc. | 2025 | Michael Exton | 650,576 | 1,049,304 | 1,355,231 | 0 | 3,553,953 |
| 17 | Aquestive Therapeutics Inc. | 2025 | Daniel Barber | 659,885 | 1,547,342 | 877,200 | 409,132 | 3,493,559 |
| 18 | Siga Technologies Inc. | 2025 | Diem Nguyen | 927,000 | 1,853,992 | 0 | 0 | 3,244,492 |
| 19 | Ironwood Pharmaceuticals Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 20 | Collegium Pharmaceutical Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Aurinia Pharmaceuticals | not disclosed | not disclosed | not disclosed | WTW |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Aquestive Therapeutics Inc. | not disclosed | Options 42 · PSU 30 · RSU 28 | No | Aon |
| Arcutis Biotherapeutics Inc. | 125% | not disclosed | No | Pay Governance LLC |
| ARS Pharmaceuticals Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Collegium Pharmaceutical Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Day One Biopharmaceuticals Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Evolus Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Innoviva Inc. | 105% | not disclosed | not disclosed | Meridian |
| Ironwood Pharmaceuticals Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Lexicon Pharmaceuticals Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| MiMedx Group Inc. | 115% | not disclosed | No | Willis Towers Watson |
| Pacira Biosciences Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Phathom Pharmaceuticals Inc. | 124% | not disclosed | No | Pay Governance LLC |
| Sage Therapeutics Inc. | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Siga Technologies Inc. | not disclosed | RSU 50 · PSU 50 | not disclosed | Pay Governance LLC |
| Tarsus Pharmaceuticals Inc. | 108% | Options 50 · RSU 50 | No | Pay Governance |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Urogen Pharma Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Y-mAbs Therapeutics, Inc. | 85.6% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Peter Greenleaf | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation”. As printed: 5,858,590. Filing ↗machine: r2 · c48 · span 429605–429614 |
| 2 | Section 01, Matthew Donley | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation”. As printed: 2,237,088. Filing ↗machine: r8 · c48 · span 448653–448662 |
| 3 | Section 01, Stephen Robertson | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation”. As printed: 2,126,510. Filing ↗machine: r14 · c48 · span 468727–468736 |
| 4 | Section 01, Joseph Miller | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation”. As printed: 2,102,747. Filing ↗machine: r5 · c48 · span 439304–439313 |
| 5 | Section 01, Gregory Keenan | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation”. As printed: 1,774,241. Filing ↗machine: r11 · c48 · span 458683–458692 |
| 6 | Section 03, Joseph Miller PSU | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Matthew Donley PSU | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Peter Greenleaf PSU | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 501518–501527 |
| 9 | Section 03, Gregory Keenan PSU | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Stephen Robertson PSU | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Peter Greenleaf OPTION | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 505322–505331 |
| 12 | Section 03, Gregory Keenan OPTION | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 539407–539414 |
| 13 | Section 03, Matthew Donley OPTION | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 528712–528719 |
| 14 | Section 03, Joseph Miller OPTION | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 516680–516687 |
| 15 | Section 03, Stephen Robertson OPTION | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 551442–551449 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “CEO Pay Ratio”. As printed: 18 : 1. Filing ↗ |
| 17 | Section 08, Tina S. Nova, Ph.D | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 374,157. Filing ↗machine: span 885856–886373 |
| 18 | Section 08, Kathy Goetz | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 372,694. Filing ↗machine: span 884011–884528 |
| 19 | Section 08, Craig Johnson | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 276,686. Filing ↗machine: span 882174–882691 |
| 20 | Section 08, Jeffrey Bailey | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 274,873. Filing ↗machine: span 880511–881028 |
| 21 | Section 08, Jill Leversage | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 17,438. Filing ↗machine: span 891594–891882 |
| 22 | Section 08, Dr. Karen Smith | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 17,251. Filing ↗machine: span 889752–890040 |
| 23 | Section 08, Dr. David R.W. Jayne | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 17,063. Filing ↗machine: span 887912–888200 |
| 24 | Section 08, Kevin Tang | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 08, Former Directors | DEF 14A | 2026-04-21 | 0001600620-26-000039 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 26 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001600620-26-000053 | Item 5.07 · say-on-pay result. As reported: 93.9% (votes for as printed: 66,398,971). Filing ↗ |
| 27 | Section 06, 2025 vote | Form 8-K | 2025-05-15 | 0001600620-25-000057 | Item 5.07 · say-on-pay result. As reported: 77.4% (votes for as printed: 58,851,313). Filing ↗ |
| 28 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001600620-24-000087 | Item 5.07 · say-on-pay result. As reported: 40.45% (votes for as printed: 30,780,033). Filing ↗ |
| 29 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 30 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 31 | Section 09b board cost (computed) | Computed | — | — | Cash 270,176 + equity 0 + all other 0 = 270,176, summed across the director compensation table rows.machine: formula: Σ = 270,176 |
| 32 | Pacira Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira Biosciences Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 33 | ANI Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 34 | ARS Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191433 | CEO total compensation as printed in ARS Pharmaceuticals Inc.'s own proxy. As printed: 9,656,400. Filing ↗ |
| 35 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 36 | Arcutis Biotherapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001787306-26-000028 | CEO total compensation as printed in Arcutis Biotherapeutics Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824 |
| 37 | MiMedx Group Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001376339-26-000033 | CEO total compensation as printed in MiMedx Group Inc.'s own proxy. As printed: 7,182,208. Filing ↗machine: t18 · r2 · c29 · span 444167–444176 |
| 38 | Sage Therapeutics Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-058060 | CEO total compensation as printed in Sage Therapeutics Inc.'s own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793 |
| 39 | Phathom Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144570 | CEO total compensation as printed in Phathom Pharmaceuticals Inc.'s own proxy. As printed: 6,968,070. Filing ↗machine: r2 · c21 · span 619155–619164 |
| 40 | Tarsus Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001819790-26-000028 | CEO total compensation as printed in Tarsus Pharmaceuticals Inc.'s own proxy. As printed: 6,617,979. Filing ↗machine: span 448592–448601 |
| 41 | Day One Biopharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals Inc.'s own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 42 | Evolus Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001570562-26-000059 | CEO total compensation as printed in Evolus Inc.'s own proxy. As printed: 6,412,214. Filing ↗machine: span 499358–499367 |
| 43 | Aurinia Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001600620-26-000039 | CEO total compensation as printed in Aurinia Pharmaceuticals's own proxy. As printed: 5,858,590. Filing ↗machine: r2 · c48 · span 429605–429614 |
| 44 | Innoviva Inc., Section 10b CEO total | DEF 14A | 2026-03-24 | 0001140361-26-010912 | CEO total compensation as printed in Innoviva Inc.'s own proxy. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487 |
| 45 | Y-mAbs Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics, Inc.'s own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604 |
| 46 | Urogen Pharma Ltd., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014237 | CEO total compensation as printed in Urogen Pharma Ltd.'s own proxy. As printed: 4,310,624. Filing ↗machine: r1 · c29 · span 562926–562935 |
| 47 | Lexicon Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001062822-26-000056 | CEO total compensation as printed in Lexicon Pharmaceuticals Inc.'s own proxy. As printed: 3,553,953. Filing ↗machine: t16 · r2 · c25 · span 400176–400185 |
| 48 | Aquestive Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016757 | CEO total compensation as printed in Aquestive Therapeutics Inc.'s own proxy. As printed: 3,493,559. Filing ↗machine: r2 · c21 · span 397882–397891 |
| 49 | Siga Technologies Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017421 | CEO total compensation as printed in Siga Technologies Inc.'s own proxy. As printed: 3,244,492. Filing ↗machine: r2 · c24 · span 426609–426618 |
| 50 | Ironwood Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050325 | CEO total compensation as printed in Ironwood Pharmaceuticals Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191 |
| 51 | Collegium Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 52 | Section 10a, Siga Technologies Inc. reciprocity | DEF 14A | — | 0001140361-26-017421 | Siga Technologies Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 53 | Section 10a, Lexicon Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001062822-26-000056 | Lexicon Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 54 | Section 10a, Day One Biopharmaceuticals Inc. reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 55 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 56 | Section 10a, Sage Therapeutics Inc. reciprocity | DEF 14A | — | 0000950170-25-058060 | Sage Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 57 | Section 10a, Innoviva Inc. reciprocity | DEF 14A | — | 0001140361-26-010912 | Innoviva Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 58 | Section 10a, Pacira Biosciences Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira Biosciences Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 59 | Section 10a, ARS Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-191433 | ARS Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 60 | Section 10a, MiMedx Group Inc. reciprocity | DEF 14A | — | 0001376339-26-000033 | MiMedx Group Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 61 | Section 10a, Evolus Inc. reciprocity | DEF 14A | — | 0001570562-26-000059 | Evolus Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 62 | Section 10a, Collegium Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 63 | Section 10a, Tarsus Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001819790-26-000028 | Tarsus Pharmaceuticals Inc. names Aurinia Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 64 | Section 10a, Arcutis Biotherapeutics Inc. reciprocity | DEF 14A | — | 0001787306-26-000028 | Arcutis Biotherapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 65 | Section 10a, ANI Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals, Inc. names Aurinia Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 66 | Section 10a, Y-mAbs Therapeutics, Inc. reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 67 | Section 10a, Urogen Pharma Ltd. reciprocity | DEF 14A | — | 0001437749-26-014237 | Urogen Pharma Ltd.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |
| 68 | Section 10a, Ironwood Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001104659-26-050325 | Ironwood Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Aurinia Pharmaceuticals. Filing ↗ |